Molecular Axiom
Latest round
- Series A
Last raised
- Dec 2022
Total raised
- Undisclosed
Investors
- 3
About Molecular Axiom
Based in Shanghai, China, and established in 2022, Molecular Axiom is a biotechnology company that focuses on the R&D of nucleic acid drugs for cancers. Dr. Bohan Le, the company's co-founder, is a serial entrepreneur, who co-established Fronthera Pharmaceuticals, and three projects of Fronthera Pharmaceuticals entered the clinical phase, and one drug sold USD 180 million to Foresite Capital in March 2021. Dr. Lishan Chen, the company's co-founder, established the nucleic drugs R&D platform, and the R&D of nucleic acid drug delivery technologies. Molecular Axiom engages in the R&D of nucleic acid drugs for central nervous system diseases, lung diseases, and skin diseases. It also focuses on nucleic acid drug delivery technologies. And it developed nucleic acid drug inhalation delivery technology for cancers and inflammatory diseases.
Who invested in Molecular Axiom
3 investors across 1 round
See all investors in Molecular Axiom
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 14, 2022
Amount
Undisclosed
Investors
Questions about Molecular Axiom
Who invested in Molecular Axiom?
Molecular Axiom has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Molecular Axiom raised?
Molecular Axiom has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Molecular Axiom last raise money?
Molecular Axiom's most recent round on record is a Series A, in Dec 2022.
What does Molecular Axiom do?
Based in Shanghai, China, and established in 2022, Molecular Axiom is a biotechnology company that focuses on the R&D of nucleic acid drugs for cancers.
Where is Molecular Axiom headquartered?
Molecular Axiom is headquartered in Shanghai, China.
Which VCs invest in companies like Molecular Axiom?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Molecular Axiom's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Molecular Axiom? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.